Vaccine protection against Bacillus cereus-mediated respiratory anthrax-like disease in mice

So Young Oh, Hannah Maier, Jay Schroeder, G. Stefan Richter, Derek Elli, James M. Musser, Lauriane E. Quenee, Dominique M. Missiakas, Olaf Schneewinda

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Bacillus cereus strains harboring a pXO1-like virulence plasmid cause respiratory anthrax-like disease in humans, particularly in welders. We developed mouse models for intraperitoneal as well as aerosol challenge with spores of B. cereus G9241, harboring pBCXO1 and pBC218 virulence plasmids. Compared to wild-type B. cereus G9241, spores with a deletion of the pBCXO1-carried protective antigen gene (pagA1) were severely attenuated, whereas spores with a deletion of the pBC218-carried protective antigen homologue (pagA2) were not. Anthrax vaccine adsorbed (AVA) immunization raised antibodies that bound and neutralized the pagA1-encoded protective antigen (PA1) but not the PA2 orthologue encoded by pagA2. AVA immunization protected mice against a lethal challenge with spores from B. cereus G9241 or B. cereus Elc4, a strain that had been isolated from a fatal case of anthrax-like disease. As the pathogenesis of B. cereus anthrax-like disease in mice is dependent on pagA1 and PAneutralizing antibodies provide protection, AVA immunization may also protect humans from respiratory anthrax-like death.

Original languageEnglish (US)
Pages (from-to)1008-1017
Number of pages10
JournalInfection and Immunity
Issue number3
StatePublished - Mar 2013

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Immunology
  • Infectious Diseases


Dive into the research topics of 'Vaccine protection against Bacillus cereus-mediated respiratory anthrax-like disease in mice'. Together they form a unique fingerprint.

Cite this